Trial Profile
Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Nov 2012
Price :
$35
*
At a glance
- Drugs Levosalbutamol (Primary)
- Indications Cutaneous lupus erythematosus
- Focus Therapeutic Use
- 23 Aug 2011 New trial record